![]() |
Indication of major added benefit for trastuzumab emtansine in metastatic breast canc
Added benefit not proven in three further subpopulations because appropriate comparator therapies were not implementedThe antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has...
More... |
| All times are GMT -7. The time now is 10:49 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021